Other tests like x-rays, CAT scans, and MRIs can suggest that cancer is present, but only an examination of a piece of the tumor can make a definite diagnosis. Types
Pleuropulmonary blastoma is classified into 3 types:

Type I is multicystic
Type II shows thickening areas (nodules) within this cystic lesion
Type III shows solid masses.Type I PPB is made up of mostly cysts, and may be hard to distinguish from benign lung cysts, and there is some evidence that not all type I PPB will progress to types II and III. Types II and III are aggressive, and cerebral metastasis is more frequent in PPB than in other childhood sarcomas. Treatment
Treating PPB depends on the size and location of the tumor, whether the cancer has spread, and the childs overall health. Surgery is the main treatment for PPB. The main goal of surgery is to remove the tumor. If the tumor is too large to be completely removed, or if its not possible to completely remove the tumor, surgery may be performed after chemotherapy. Because PPB can return after treatment, regular screening for possible recurrence should continue for 48 to 60 months, after diagnosis. History
Pleuropulmonary blastoma was first described in 1988.An international registry has been established. See also
Lung cancer

References


== External links ==
Side effects
Like pure MOR agonists, the mixed agonist/antagonist opioid class of drugs can cause side effects with initial administration of the drug which lessens over time (“tolerance”). This is particularly true for the side effects of nausea, sedation and cognitive symptoms (Jovey et al. 2003). These side effects can in many instances be ameliorated or avoided at the time of drug initiation by titrating the drug from a tolerable starting dose up to the desired therapeutic dose. An important difference between nalbuphine and the pure MOR agonist opioid analgesic drugs is the “ceiling effect” on respiration (but no ceiling on the analgesic effect). Respiratory depression is a potentially fatal side effect from the use of pure MOR agonists. Nalbuphine has limited ability to depress respiratory function (Gal et al. 1982). As reported in the current Nubain Package Insert (2005), the most frequent side effect in 1066 patients treated with nalbuphine was sedation in 381 (36%). Other, less frequent reactions are: feeling sweaty/clammy 99 (9%), nausea/vomiting 68 (6%), dizziness/vertigo 58 (5%), dry mouth 44 (4%), and headache 27 (3%). Other adverse reactions which may occur (reported incidence of 1% or less) are:

CNS effects: Nervousness, depression, restlessness, crying, euphoria, flushing, hostility, unusual dreams, confusion, faintness, hallucinations, dysphoria, feeling of heaviness, numbness, tingling, unreality. The incidence of psychotomimetic effects, such as unreality, depersonalization, delusions, dysphoria and hallucinations has been shown to be less than that which occurs with pentazocine. Cardiovascular: Hypertension, hypotension, bradycardia, tachycardia, pulmonary edema. Gastrointestinal: Cramps, dyspepsia, bitter taste. Respiration: Depression, dyspnea, asthma. Dermatological: Itching, burning, urticaria.